image
Basic Materials - Chemicals - Specialty - NYSE - US
$ 15.23
0.661 %
$ 10.4 B
Market Cap
14.64
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AVTR stock under the worst case scenario is HIDDEN Compared to the current market price of 15.2 USD, Avantor, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AVTR stock under the base case scenario is HIDDEN Compared to the current market price of 15.2 USD, Avantor, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AVTR stock under the best case scenario is HIDDEN Compared to the current market price of 15.2 USD, Avantor, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AVTR

image
$26.0$26.0$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
6.78 B REVENUE
-2.64%
1.08 B OPERATING INCOME
55.77%
712 M NET INCOME
121.58%
841 M OPERATING CASH FLOW
-3.36%
439 M INVESTING CASH FLOW
405.43%
-1.28 B FINANCING CASH FLOW
-51.85%
1.69 B REVENUE
-1.62%
638 M OPERATING INCOME
412.12%
500 M NET INCOME
765.74%
173 M OPERATING CASH FLOW
-29.21%
558 M INVESTING CASH FLOW
1479.01%
-755 M FINANCING CASH FLOW
-280.31%
Balance Sheet Avantor, Inc.
image
Current Assets 2.15 B
Cash & Short-Term Investments 262 M
Receivables 1.03 B
Other Current Assets 850 M
Non-Current Assets 9.97 B
Long-Term Investments 0
PP&E 708 M
Other Non-Current Assets 9.26 B
8.54 %7.02 %5.85 %76.44 %Total Assets$12.1b
Current Liabilities 2.01 B
Accounts Payable 663 M
Short-Term Debt 821 M
Other Current Liabilities 524 M
Non-Current Liabilities 4.15 B
Long-Term Debt 0
Other Non-Current Liabilities 4.15 B
10.76 %13.33 %8.50 %67.40 %Total Liabilities$6.2b
EFFICIENCY
Earnings Waterfall Avantor, Inc.
image
Revenue 6.78 B
Cost Of Revenue 4.5 B
Gross Profit 2.28 B
Operating Expenses 1.19 B
Operating Income 1.08 B
Other Expenses 373 M
Net Income 712 M
7b7b6b6b5b5b4b4b3b3b2b2b1b1b007b(5b)2b(1b)1b(373m)712mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
33.60% GROSS MARGIN
33.60%
15.99% OPERATING MARGIN
15.99%
10.49% NET MARGIN
10.49%
11.94% ROE
11.94%
5.87% ROA
5.87%
8.27% ROIC
8.27%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Avantor, Inc.
image
1b1b800m800m600m600m400m400m200m200m00(200m)(200m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 712 M
Depreciation & Amortization 406 M
Capital Expenditures -149 M
Stock-Based Compensation 46.8 M
Change in Working Capital 0
Others -276 M
Free Cash Flow 692 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Avantor, Inc.
image
Wall Street analysts predict an average 1-year price target for AVTR of $26.7 , with forecasts ranging from a low of $24.5 to a high of $28 .
AVTR Lowest Price Target Wall Street Target
24.5 USD 60.87%
AVTR Average Price Target Wall Street Target
26.7 USD 75.09%
AVTR Highest Price Target Wall Street Target
28 USD 83.85%
Price
Max Price Target
Min Price Target
Average Price Target
28282626242422222020181816161414May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Avantor, Inc.
image
Sold
0-3 MONTHS
183 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
361 K USD 2
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Avantor® Showcases Scalable Fluid Handling Innovations at INTERPHEX Industry leading set of technologies to drive scalability, flexibility, and efficiency in biologics production RADNOR, Pa. , April 1, 2025 /PRNewswire/ -- Avantor®, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, announces its presence at INTERPHEX, the premier annual gathering of pharmaceutical, biotechnology, and device development and manufacturing professionals. prnewswire.com - 2 weeks ago
Avantor® to Report First Quarter 2025 Earnings on Friday, April 25, 2025 RADNOR, Pa. , March 28, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2025 financial results before the market opens on Friday, April 25, and will hold a conference call to discuss the results on the same day at 8:00 a.m. prnewswire.com - 3 weeks ago
Here's Why You Should Hold AVTR Stock in Your Portfolio for Now Avantor is set for growth with a strong portfolio and solid fourth quarter results, but challenges like customer losses and forex volatility pose potential risks. zacks.com - 3 weeks ago
Avantor® Provides First Look at Recently Completed Hydration Expansion at DCAT Week 2025 Facility in Gliwice, Poland to boost biopharma manufacturers' efficiency and speed to market of therapies RADNOR, Pa. , March 17, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services in the life sciences and advanced technology industries, announces that Ger Brophy, PhD, head of Avantor's Scientific Advisory Board, will present highlights of the recently completed expansion at its flagship European manufacturing site at Drug, Chemical & Associated Technologies Association (DCAT) Week 2025. prnewswire.com - 1 month ago
Avantor® to Present at TD Cowen's 45th Annual Health Care Conference RADNOR, Pa. , Feb. 19, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that President and CEO, Michael Stubblefield, will present at TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, at 11:50 a.m. prnewswire.com - 1 month ago
Silq Technologies Corp. and NuSil Technology LLC Announce Collaboration Agreement to Drive Broad-based Adoption of Silq's Novel Surface Treatment Technology SUNNY ISLES BEACH, Fla.--(BUSINESS WIRE)--Silq Technologies Corporation, a privately held advanced materials science company, and NuSil Technology LLC, a subsidiary of Avantor Inc., Radnor, Pa. (NYSE: AVTR), and a leading global supplier of high-quality silicones for long-term medical implants, have entered into an agreement to facilitate the utilization of Silq's zwitterionic surface treatment technology on medical devices manufactured with NuSil silicone products. Zwitterion surface technolog. businesswire.com - 1 month ago
Avantor Stock Declines Despite Q4 Earnings Beat, Margins Expand Despite AVTR's stability in proprietary chemicals and specialty procurement sales, it reports an overall soft fourth-quarter performance. zacks.com - 2 months ago
Avantor, Inc. (AVTR) Q4 2024 Earnings Call Transcript Avantor, Inc. (NYSE:AVTR ) Q4 2024 Earnings Conference Call February 7, 2025 8:00 AM ET Company Participants Allison Hosak - SVP of Global Communications Michael Stubblefield - President and CEO Brent Jones - EVP and CFO Conference Call Participants Vijay Kumar - Evercore ISI Michael Ryskin - Bank of America Daniel Brennan - TD Cowen Rachel Vatnsdal - JP Morgan Tycho Peterson - Jefferies Luke Sergott - Barclays Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Conor McNamara - RBC Capital Markets Ivy Ma - Goldman Sachs Brandon Couillard - Wells Fargo Jack Meehan - Nephron Research Operator Hello everybody and a warm welcome to Avantor's Fourth Quarter 2024 Earnings Call. My name is Emily and I'll be coordinating your call today. seekingalpha.com - 2 months ago
Avantor (AVTR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Avantor (AVTR) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 2 months ago
Life Science Tools Firm Avantor Reports Mixed Q4 Earnings, Forecasts Organic Sales Growth In 2025 On Friday, Avantor Inc AVTR reported fourth-quarter net sales of $1.69 billion, a decrease of 2% year-over-year, missing the consensus of $1.71 billion. benzinga.com - 2 months ago
Avantor, Inc. (AVTR) Surpasses Q4 Earnings Estimates Avantor, Inc. (AVTR) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.25 per share a year ago. zacks.com - 2 months ago
Avantor® Reports Fourth Quarter and Full Year 2024 Results Fourth Quarter 2024 Net sales of $1.69 billion, decrease of 2%; organic growth of 1% Net income of $500.4 million; Adjusted EBITDA of $307.7 million Diluted GAAP EPS of $0.73; adjusted EPS of $0.27 Operating cash flow of $173.3 million; free cash flow of $222.1 million Full Year 2024 Net sales of $6.78 billion, decrease of 3%; organic decline of 2% Net income of $711.5 million; Adjusted EBITDA of $1,198.8 million Diluted GAAP EPS of $1.04; adjusted EPS of $0.99 Operating cash flow of $840.8 million; free cash flow of $768.3 million RADNOR, Pa. , Feb. 7, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its fourth fiscal quarter and year ended December 31, 2024. prnewswire.com - 2 months ago
8. Profile Summary

Avantor, Inc. AVTR

image
COUNTRY US
INDUSTRY Chemicals - Specialty
MARKET CAP $ 10.4 B
Dividend Yield 0.00%
Description Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Contact Radnor Corporate Center, Radnor, PA, 19087 https://www.avantorsciences.com
IPO Date May 17, 2019
Employees 13500
Officers Mr. Michael Stubblefield President, Chief Executive Officer & Director Mr. R. Brent Jones Executive Vice President & Chief Financial Officer